Comparative Study of Obinutuzumab (GA101) Vs. Rituximab Against CD20+ rituximab-Sensitive and -Resistant Burkitt (BL) and Acute Lymphoblastic Leukemia (B-ALL): Potential Targeted Therapy in Patients with High Risk BL and Pre-B-ALL

Autor: Awasthi, Aradhana *, Ayello, Janet *, van de Ven, Carmella *, Elmacken, Mona *, Reggio, Christopher *, Barth, Matthew J., Cairo, Mitchell S.
Zdroj: In Blood 6 December 2014 124(21):2251-2251
Databáze: ScienceDirect